<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084448</url>
  </required_header>
  <id_info>
    <org_study_id>GOG_0126P</org_study_id>
    <nct_id>NCT00084448</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation of Weekly Paclitaxel (NSC #673089) and Celecoxib (Celebrex®, NSC #719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of&#xD;
      cancer by stopping blood flow to the tumor and may increase the effectiveness of paclitaxel&#xD;
      by making tumor cells more sensitive to the drug. Giving celecoxib together with paclitaxel&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel together with celecoxib&#xD;
      works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial&#xD;
      or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of paclitaxel and celecoxib in patients with recurrent&#xD;
           or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.&#xD;
&#xD;
        -  Determine the nature and degree of toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and oral celecoxib twice&#xD;
      daily on days 2-6, 9-13, and 16-27. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 11-22&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal cancer&#xD;
&#xD;
               -  Recurrent or persistent disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional&#xD;
                  techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  At least 1 target lesion not in a previously irradiated field&#xD;
&#xD;
          -  Must have received 1 prior platinum-based chemotherapy regimen for primary disease&#xD;
             containing carboplatin, cisplatin, or another organoplatinum compound&#xD;
&#xD;
               -  Initial treatment may have included high-dose therapy, consolidation, or extended&#xD;
                  therapy administered after surgical or non-surgical assessment&#xD;
&#xD;
               -  Platinum-resistant or refractory (i.e., had a treatment-free interval after&#xD;
                  platinum therapy of less than 6 months OR disease progression during&#xD;
                  platinum-based therapy)&#xD;
&#xD;
               -  Patients who have not received a prior taxane may have received a second regimen&#xD;
                  that included paclitaxel or docetaxel&#xD;
&#xD;
          -  Must not be eligible for a higher priority GOG protocol&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No neuropathy (sensory and motor) &gt; grade 1&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
          -  No allergies to sulfa or non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No known hypersensitivity to paclitaxel or celecoxib&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except non-melanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior biologic or immunologic therapy&#xD;
&#xD;
          -  One prior non-cytotoxic* regimen for recurrent or persistent disease allowed NOTE:&#xD;
             *Non-cytotoxic (biologic or cytostatic) agents include (but are not limited to)&#xD;
             monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No other prior cytotoxic chemotherapy for recurrent or persistent disease, including&#xD;
             retreatment with initial chemotherapy regimen&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy for malignant tumor&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of marrow-bearing areas&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior therapy for malignant tumor&#xD;
&#xD;
          -  No prior celecoxib&#xD;
&#xD;
          -  No prior therapy for a previous cancer that would preclude protocol therapy&#xD;
&#xD;
          -  No concurrent amifostine or other protective agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte E. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 8, 2013</last_update_submitted>
  <last_update_submitted_qc>July 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

